Connect with us

Hi, what are you looking for?


Longeveron Announces Clinical Collaboration to Study Cell Therapy Aging Treatment in Japan: Why It Matters

Longeveron Inc. (NASDAQ: LGVN) announced Friday a clinical trial collaboration to study its lead investigational asset, Lomecel-B.

What Happened: Florida-based Longeverson said it has entered into a sponsored clinical research agreement with Japan’s National Center for Geriatrics and Gerontology and the Juntendo University Hospital to study Lomcecel-B in older, frail Japanese subjects.

The Japanese Phase 2 study, approved by Japan’s Pharmaceuticals and Medical Devices Agency, has a target enrollment of 45 subjects in three cohorts, randomized to receive a single intravenous infusion of Lomecel-B 50 million cells, Lomecel-B 100 million cells, or a placebo.

The primary objective is to evaluate the safety and explore the effect of Lomecel-B on physical function, activities of daily living, inflammation-related …

Full story available on

Original Article:

Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like


Arbutus’ Lead Compound AB-729 Continues to be Safe and Effective at Reducing HBsAg in Patients with Chronic Hepatitis B HBsAg remains suppressed up to...


The Fourth Single ‘Eyy Bidda Idhi Naa Adda’ From Allu Arjun’s Pushpa Is Out… The Fourth Single ‘Eyy Bidda Idhi Naa Adda’ From Allu...


Kyle Rittenhouse testifies about Gaige Grosskreutz holding a gun toward him during his trial at the Kenosha County Courthouse on November 10, 2021 in...


PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC, the “Company”)), a biotechnology company with operations in China and the...